NANJING, Jan. 7 (Xinhua) -- Precision oncology firm Genetron Health has formed a strategic partnership with a pharmaceutical company in east China's Jiangsu Province to jointly promote early screening for liver cancer in China.
According to the agreement signed on Wednesday with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ) in the provincial capital Nanjing, the companies will work together to promote the use of HCCscreen, a Genetron Health blood-based early screening testing product, in Chinese hospitals.
The product targets individuals at high risk of liver cancer, including carriers of the hepatitis B virus (HBV).
"We expect this strategic partnership to bring us closer to our goal of lowering liver cancer-related death rates in China," said Wang Sizhen, co-founder and CEO of Genetron Health.
Based in Beijing, Genetron Health is a precision oncology company providing genomic profiling solutions in areas including early cancer screening, diagnosis and monitoring, as well as biopharmaceutical services.
CTTQ is a multinational pharmaceutical company with integrated research and development, manufacturing, marketing, sales and distribution capabilities. It is based in Lianyungang, Jiangsu Province.
Liver cancer is one of the most common causes of cancer-related deaths worldwide. Market data released by consulting and research firm Frost and Sullivan in 2019 showed that among the 120 million people at high risk of liver cancer in China, around 74 million were HBV carriers. Enditem